Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

Pharma majors AbbVie and Roche were both trading lower early Tuesday after top-line results were announced from the global ...

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

A new hereditary condition has been discovered that affects patients' ability to repair DNA—leaving them both at greater risk ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Retail investor chatter around Bristol Myers Squibb intensified on Monday following the release of new clinical data, which ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

A new hereditary condition has been discovered that affects patients' ability to repair DNA – leaving them both at greater ...

The company stated that no safety signals were observed in the study comparing the efficacy and safety of Venetoclax in ...